NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$502.60
+7.96 (+1.61 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$495.86
Now: $502.60
$506.87
50-Day Range
$446.73
MA: $471.05
$496.01
52-Week Range
$441.00
Now: $502.60
$664.64
Volume1.17 million shs
Average Volume1.02 million shs
Market Capitalization$53.84 billion
P/E Ratio18.37
Dividend YieldN/A
Beta0.3
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000
Employees9,123
Year Founded1988

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$23.77 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Market Cap$53.84 billion
Next Earnings Date5/6/2021 (Confirmed)
OptionableOptionable

Headlines

Here's How I'd Treat Regeneron
April 14, 2021 |  realmoney.thestreet.com
See More Headlines

MarketRank

Overall MarketRank

2.61 out of 5 stars

Medical Sector

6th out of 2,024 stocks

Pharmaceutical Preparations Industry

3rd out of 772 stocks

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 4.4 5 -4 -3 -2 -1 -
$502.60
+7.96 (+1.61 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 5 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Thursday, February, 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, beating analysts' consensus estimates of $7.11 by $2.42. The biopharmaceutical company earned $2.42 billion during the quarter, compared to the consensus estimate of $2.40 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 28.97% and a net margin of 38.28%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm earned $7.50 earnings per share.
View Regeneron Pharmaceuticals' earnings history
.

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 8.2% and is now trading at $502.60.
View which stocks have been most impacted by COVID-19
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a share buyback plan on Tuesday, November 5th 2019, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its stock is undervalued.

What price target have analysts set for REGN?

20 brokerages have issued twelve-month price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $510.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $646.26 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 68, Pay $4.77M)
  • Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 61, Pay $3.98M) (LinkedIn Profile)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 57, Pay $1.56M) (LinkedIn Profile)
  • Dr. Andrew J. Murphy, Exec. VP of Research (Age 63, Pay $1.29M)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 48, Pay $1.46M)
  • Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. Fenimore, Sr. VP, Head of Accounting & Controller (Age 50)
  • Mr. Gerald Underwood, Sr. VP of Technical Operations
  • Mr. Bob McCowan, Sr. VP of IT & Chief Information Officer
  • Justin Holko, VP of Investor Relations

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.09%), Bronte Capital Management Pty Ltd. (0.06%), DnB Asset Management AS (0.04%), Royal London Asset Management Ltd. (0.03%), State of Alaska Department of Revenue (0.03%) and Hexavest Inc. (0.02%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including FDx Advisors Inc., Hexavest Inc., NuWave Investment Management LLC, State of Alaska Department of Revenue, Veracity Capital LLC, Pacer Advisors Inc., Keudell Morrison Wealth Management, and Chesley Taft & Associates LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bronte Capital Management Pty Ltd., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, DnB Asset Management AS, UMB Bank N A MO, Founders Capital Management LLC, Everence Capital Management Inc., and Clear Harbor Asset Management LLC.
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $502.60.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $53.84 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, OSMR LLC, Old Saw Mill Holdings LLC, Regeneron Assurance, Regeneron Atlantic Holdings, Regeneron Belgium BVBA, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron Healthcare Solutions, Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron Spain, Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.